BioSpace News Archive

Ginkgo Bioworks Holdings, Inc., the leading horizontal platform for cell programming, announced its results for the third quarter ended September 30, 2021.

Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, announced that members of its leadership team will present at the following investor conferences in November and December.

ImmunoGenesis announced today that preclinical data from its lead development programs were presented in six scientific posters at the Society for Immunotherapy of Cancer 36th Annual Meeting (SITC 2021), which was held November 10-14, 2021

Cybin Inc. today reported unaudited financial results for its second quarter ended September 30, 2021.

9 Meters Biopharma, Inc. today provided a business update and reported financial results for the third quarter ended September 30, 2021.

Rhythm Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the company’s supplemental New Drug Application (sNDA) for IMCIVREE® (setmelanotide)

The EspeRare Foundation and the Pierre Fabre group announced today the start of the EDELIFE clinical trial aimed at confirming the safety and efficacy of ER004, a prenatal treatment for XLHED (X-linked Hypohidrotic Ectodermal Dysplasia), a rare and debilitating congenital disease.

Ayala Pharmaceuticals, Inc. today reported financial results for the period ended September 30, 2021 and highlighted recent progress and upcoming milestones for its pipeline programs.

Surrozen, Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, announced today that data from its liver disease program, including preclinical studies of SZN-043 showing improved liver metabolic function, were presented during The Liver Meeting 2021.

Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced that it presented results from a preclinical study of a research form of KER-012 (“RKER-012”) at the American Heart Association (“AHA”) 2021 Scientific Sessions held November 13 through 15, 2021.